
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is positioned for strong growth in the biopharma sequencing and diagnostics markets, with a diverse and impressive product portfolio and a highly scalable AI platform. Its recent FDA clearance for Tempus ECG-PH expands its addressable market and reinforces the potential for its ECG-AI platform. With a strong track record in precision medicine diagnostics and a partnership with Merck and Moderna, Tempus AI is poised for significant revenue growth and potential partnerships with other biopharma companies. Although there are some risks to achievement of its $73 price target, the company remains a top performer in the healthcare technology space and is well-positioned for success in the future.
Bears say
Tempus AI is facing significant risks in the near future due to its high dependency on Medicare coverage and partnerships with other companies for its AI-driven diagnostic and testing platforms. Its recent acquisition of Personalis may add value, but full commercialization has yet to be achieved. Additionally, the lack of formal CDx designation for Intismeran may hinder its revenue potential, making it difficult for Tempus AI to achieve sustainable profitability.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares